Ann: December 2020 Quarterly Update and Appendix 4C, page-13

Im just going to put this out there.... This stock is so strong I believe a true re-rate is coming... obviously the report today was very encouraging, but I have a sense there is something ground breaking to come... the strength here on a blood bath day was exceptional... a little gutted that I didn't get my 10cent order filled.... but that's ok... happy with my lot

over $2million churn today... well done to holders that haven't let go...

biotech companies such as PTX can skyrocket in a blink...have seen it numerous times... this industry offers multi millions of revenue if they succeed, even in the billions... sounds hyped and ramping, but its a fact when you look at biotech stocks that have succeeded...  a stock like this can go to $1 in a blink... mark my words... no fear of CR any time soon...

when you do some research, reports like this are circulating and gaining attention rapidly:

Special Report: Australian biotech company Prescient Therapeutics (ASX PTX) has announced what’s next for its next-generation gene therapy technology for fighting cancer.
Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer acute myeloid leukemia (AML); solid tumours including breast, ovarian and gastric cancers; and glioblastoma multiforme, the aggressive brain cancer.
Prescient’s OmniCAR technology represents a step up from the current chimeric antigen receptor T-cell (CAR T) therapy, a form of immunotherapy that involves modifying a patient’s white blood cells so they recognise and kill cancer cells.
An American woman, Laurie Adami reported how CAR T therapy saved her life by curing her stage IV follicular non-Hodgkin lymphoma.
Prescient says its OmniCAR tech is expected to be safer and more effective than the current generation of CAR T treatments, which are only a few years old.
CAR T cells using  OmniCAR  will be able to target multiple cancer antigens simultaneously, and the platform offers “persistent dosing and tumour microenvironment enhancements to improve efficacy,” Prescient says.
While OmniCAR has a range of applications, the company decided to narrow its focus to the three cancer programs after a strategic review that took into account all the known CAR T programs in development worldwide.
The company said it tried to strike a balance between the probability of technical success and being able to bring to market a differentiated, commercially viable treatment. Prescient didn’t want to risk developing a “me too” CAR T treatment that duplicated an existing therapy.
“Each of the programs represent a tremendous market opportunity,” says Prescient chief executive Steven Yatomi-Clarke.
“Furthermore, Prescient will continue to seek collaboration with external parties on additional opportunities where OmniCAR can create additional next-generation CAR therapies with partners.”
Prescient licensed OmniCAR from the University of Pennsylvania, a leader in CAR T which developed Kymriah, a Novartis therapy approved as a treatment for B-cell acute lymphoblastic leukemia (ALL).
Prescient says the vigorous development program will move OmniCAR towards the clinic while demonstrating the unique features of the technology in treating patients – adding tremendous value to the platform.

I don't know about you guys... but I'm a little excited about this one.... I admit to being a trader, any one that follows me knows I tendency to take 30% profits over and over, I minimize my risk that way... but PTX for me is a keeper, think I will see this one out...